TMDX Stock — TransMedics Group, Inc.

TransMedics Group, Inc. (TMDX)

Updated October 16, 2026.

TMDX is a Stock. Total return is 216.5% over the past 7.5 years, 24.0 points ahead of SPY at 192.5%.

TransMedics Group is a commercial-stage medical technology company that develops and provides the Organ Care System, a portable device that preserves and monitors donor organs outside the human body to improve transplant outcomes for patients with end-stage organ failure. The company's OCS platform includes specialized systems for lungs, hearts, and livers, along with organ retrieval and logistics services. The company does not currently have an established dividend distribution program.

TMDX performance versus SPY

Price and return data through 2026-10-16.

Total return is 216.5% over the past 7.5 years, 24.0 points ahead of SPY at 192.5%. Over the past year its total return — price change plus distributions reinvested — is -38.8%. Its deepest 1-year drawdown was 58.8%.

TMDX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/02/2019

Distribution frequency

None

Last close

$70.78 (as of 2026-10-16)

Market cap

$2,454,306,763

Average volume

1067831.0

Beta

1.926

Payout ratio

0.0%

P/E ratio

19.23

Forward P/E

37.3134

EPS

$3.68

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TMDX risks and drawbacks

The deepest 1-year drawdown on record here is 58.8%.

Who may consider TMDX — and who may not

It is a weaker fit for investors who need monthly cash flow (TMDX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TMDX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions